Vinblastine, bleomycin, and cis-platin as salvage therapy for MOPP treated patients with Hodgkin's lymphoma.
Seven patients with active Hodgkin's lymphoma who had relapsed 4-39 months following six or more cycles of MOPP were treated with a combination of vinblastine-bleomycin-cis-platin (VBP). Six patients attained a partial response of 1-8 months duration. There were no complete responses. The projected maximum long-term disease-free survivorship with this salvage program is less than 16%. All observed patients had Grade II-III nausea and vomiting, and neutrophil nadir counts less than 700/mm3. Three patients had platelet counts less than or equal to 85,000/mm3. This program does not have significant potential as a salvage therapy for patients with Hodgkin's lymphoma relapsing after MOPP chemotherapy.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use / Q000633:toxicity; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity; D002986:Clinical Trials as Topic; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011292:Premedication; D011344:Procarbazine / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use / Q000633:toxicity; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D002945:Cisplatin; D011241:Prednisone